NCT07024693View on ClinicalTrials.gov

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

PHASE2RecruitingINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Fuchs Endothelial Corneal DystrophyFuchs

Interventions

DRUG

DT-168

Active

Trial Locations (2)

46260

RECRUITING

DTX-168-201 Study Site, Indianapolis

49546

NOT_YET_RECRUITING

DTX-168-201 Study Site, Grand Rapids

Sponsors

Lead Sponsor

Design Therapeutics, Inc.

All Listed Sponsors

lead

Design Therapeutics, Inc.

INDUSTRY

NCT07024693 - DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | Biotech Hunter | Biotech Hunter